Novartis' (NVS) Cosentyx was recommended for expanded use to treat adolescents aged 12 and older with moderate-to-severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps and inflammation, the European Medicines Agency said Friday.
The recommendation covers adolescents who have not responded adequately to standard systemic treatments for the condition, the agency said.
The European Commission will make the final decision on the proposed change to the drug's marketing authorization, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments